Abcam, ab279967, Phosphotyrosine VEGF Receptor 3 ELISA Kit

Size: 1 x 96Tests
Phosphotyrosine VEGF Receptor 3 ELISA Kit is a Semi-quantitative ELISA for the measurement of Phosphotyrosine VEGF Receptor 3 in Human in Cell/Tissue Extracts samples.
Key facts
Detection method:Colorimetric,
Sample types:Cell Lysate,
Reacts with:Human,
Assay type:Semi-quantitative,
Assay Platform:Pre-coated microplate (12 x 8 well strips)

Product details:
Phosphotyrosine VEGF Receptor 3 ELISA Kit (ab279967) is a very rapid, convenient and sensitive assay kit that can monitor the activation or function of important biological pathways in human cell lysates. By determining phosphorylated VEGF Receptor 3 protein in your experimental model system, you can verify pathway activation in your cell lysates. You can simultaneously measure numerous different cell lysates without spending excess time and effort in performing a Western Blotting analysis.
This Sandwich ELISA kit is an
in vitro
enzyme-linked immunosorbent assay for the measurement of human phospho-VEGF Receptor 3. An anti-VEGF Receptor 3 antibody has been coated onto a 96-well plate. Samples are pipetted into the wells and phosphorylated and unphosphorylated VEGF Receptor 3 present in a sample is bound to the wells by the immobilized antibody. The wells are washed and biotinylated anti-phosphotyrosine antibody is used to detect only tyrosine-phosphorylated protein. After washing away unbound antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of phospho-VEGF Receptor 3 bound. The Stop Solution changes the color from blue to yellow, and the intensity of the color is measured at 450 nm.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
VEGF Receptor 3 also known as FLT-4 is a protein essential for lymphatic development and is expressed mainly in lymphatic endothelial cells. This receptor has a molecular mass of approximately 195 kDa. VEGF Receptor 3 belongs to the tyrosine kinase family and binds with high affinity to its ligands VEGF-C and VEGF-D. These interactions lead to the activation of intracellular signaling cascades that promote cell proliferation migration and survival.
Biological function summary
The VEGF Receptor 3 acts as an important regulator of lymphangiogenesis which is the growth of new lymphatic vessels from pre-existing ones. It is not typically part of larger protein complexes but it works closely with its ligands to facilitate the processes associated with lymph vessel formation and function. Proper activity of VEGF Receptor 3 is necessary for maintaining normal lymphatic vessel remodeling and function during development and in some adult tissues.
Pathways
The receptor is involved in the VEGF signaling pathway which plays an important role in vascular and lymphatic development. This pathway intersects with others like the PI3K/AKT pathway a critical mediator of cell growth and survival. VEGF Receptor 3 interacts with related receptors such as VEGF Receptor 2 in these pathways to regulate complex and essential physiological processes.
VEGF Receptor 3 has been linked to lymphedema which is swelling due to lymphatic system dysfunction and certain cancers where excessive angiogenesis occurs. Mutations or dysregulations in the receptor's signaling can lead to these conditions. In cancer for instance VEGF Receptor 3 along with its associated protein VEGF-C can promote tumor lymphangiogenesis facilitating metastasis. Antagonists like anti-VEGF therapies target these receptors to inhibit tumor progression and manage these disorders.